Does Australia need more catheterisation laboratories to treat heart attack?

Peter L Thompson
Med J Aust 2021; 214 (7): . || doi: 10.5694/mja2.50994
Published online: 19 April 2021

Patients receive similar treatment and have similar outcomes whether their initial hospital has cardiac catheterisation facilities or not

That early reperfusion in a cardiac catheterisation laboratory (“cath lab”) can preserve heart muscle in patients with ST‐elevation myocardial infarction (STEMI) is universally accepted,1 as captured in the “time is muscle” mantra. The reperfusion era for patients with STEMI has delivered better outcomes and reduced the number of deaths.2 Debate about whether to achieve reperfusion by lytic therapy or percutaneous coronary intervention (PCI) has also been settled, with agreement that PCI is preferable when available.3

  • Heart Research Institute, Sir Charles Gairdner Hospital, Perth, WA

Competing interests:

No relevant disclosures.

  • 1. Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST‐segment elevation. Eur Heart J 2018; 39: 119–177.
  • 2. Briffa T, Hickling S, Knuiman M, et al. Long term survival after evidence based treatment of acute myocardial infarction and revascularisation: follow‐up of population based Perth MONICA cohort, 1984–2005. BMJ 2009; 338: b36.
  • 3. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20.
  • 4. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non‐st-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 23: e139–e228.
  • 5. Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‐segment elevation. Eur Heart J 2020; ehaa575.
  • 6. Fox KAA, Clayton TC, Damman P, et al; FIR Collaboration. Long‐term outcome of a routine versus selective invasive strategy in patients with non‐ST-segment elevation acute coronary syndrome: a meta‐analysis of individual patient data. J Am Coll Cardiol 2010; 55: 2435–2445.
  • 7. Chew DP, Scott IA, Cullen L, et al; NHFA/CSANZ ACS Guideline 2016 Executive Working Group. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 2016; 25: 895–951.
  • 8. Thompson SC, Nedkoff L, Katzenellenbogen J, et al. Challenges in managing acute cardiovascular diseases and follow up care in rural areas: a narrative review. Int J Environ Res Public Health 2019; 16: 5126.
  • 9. Ayad M, Hyun K, D'Souza M, et al. Factors that influence whether patients with acute coronary syndromes undergo cardiac catheterisation. Med J Aust 2021; 214: 310–317.
  • 10. Tideman PA, Tirimacco R, Senior DP, et al. Impact of a regionalised clinical cardiac support network on mortality among rural patients with myocardial infarction. Med J Aust 2014; 200: 157–160.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.